問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Thoracic Medicine

Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Medicine

Division of Thoracic Surgery

Division of General Internal Medicine

更新時間：2023-09-19

郭漢彬Kuo, Han-Pin
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • q8828@tmu.edu.tw

Recruiting Trial

22Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

郭漢彬

List

80Cases

2009-10-01 - 2014-10-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2015-06-02 - 2019-11-30

Phase II

A Phase 2, multicenter, randomized, double-blind study of ficlatuzumab plus erlotinib versus placebo plus erlotinib in subjects who have previously untreated metastatic, EGFR-mutated non-small cell lung cancer (NSCLC) and BDX004 Positive Label.

  • Condition/Disease

    NSCLC

  • Test Drug

    Ficlatuzumab (AV-299),

Participate Sites
8Sites

Terminated7Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2021-07-27 - 2025-06-30

Phase II

A Phase II Study to Evaluate the Efficacy and Safety of FB825 in Adult Patients with Moderate-to-severe Allergic Asthma

  • Condition/Disease

    Allergic Asthma

  • Test Drug

    FB825

Participate Sites
17Sites

Not yet recruiting5Sites

Recruiting12Sites

2008-10-31 - 2012-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2013-02-01 - 2015-08-01

Phase II

A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Stage IV squamous NSCLC first line treatment.

  • Test Drug

    Necitumumab

Participate Sites
5Sites

Terminated5Sites

夏德椿
China Medical University Hospital

Division of Thoracic Medicine

2012-11-01 - 2014-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2008-07-01 - 2012-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2008-11-16 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Not yet recruiting1Sites

Terminated12Sites

2007-12-01 - 2009-01-22

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2006-02-01 - 2007-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB